ubmslateCN-logo-ubm

CN Mobile Logo

Search form

Topics:

All Content

A handful of novel antibody-based therapies may soon emerge for the treatment of acute myeloid leukemia, according to a presentation at the 21st Annual International Congress on Hematologic Malignancies.

In patients with breast cancer with a recurrence score based on a 21-gene expression assay of 11 to 25, outcomes were similar whether chemotherapy was used or not.

Cessation of second-generation TKIs yielded good treatment-free remission rates in patients with chronic myeloid leukemia who had sustained deep molecular responses.

Men with painful bone metastases from prostate cancer may be able to achieve clinically meaningful improvements in pain and quality of life as early as 10 days after undergoing radiotherapy.

Significant progress has been made in the treatment of chronic lymphocytic leukemia with the addition of options such as the tyrosine kinase inhibitor ibrutinib, the monoclonal antibody obinutuzumab, and the BCL2 inhibitor venetoclax.

In this interview we discuss clinical developments in essential thrombocythemia, polycythemia vera, and myelofibrosis, as well as the latest treatment options.

Three courses of clofarabine combined with cytarabine may improve relapse-free survival in patients with acute myeloid leukemia in first remission.

Smoking is linked to mortality and to disease progression among patients with chronic myeloid leukemia.

New treatment options are now available for light-chain amyloidosis, with additional ones on the way, according to a presentation at the 21st Annual International Congress on Hematologic Malignancies.

Patients participating in cancer clinical trials were willing and able to report symptomatic adverse events and reported more events than investigators did.

Pages

By clicking Accept, you agree to become a member of the UBM Medica Community.